Arkolith/Insider Trading/AVTX/Form 4

Doyle Mittie

Chief Medical OfficerAvalo Therapeutics, Inc. (AVTX) · full profile →Form 4 · filed Jul 2, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$93K
Net Open-Market Flow
-$93K
Transactions
5
3 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 30, 2026Option exercise(M)3K$12.65$36K55K
Jun 30, 2026Option exercise(M)2K$8.04$14K56K
Jun 30, 2026Sell(S)5K$20.00$93K52K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 30, 2026Option exercise(M)3K—$0126K
Jun 30, 2026Option exercise(M)2K—$0115K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001918845-26-000022) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML